Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4100511 DDI Study with Probe Substrates in Healthy Participants
NCT06503679Phase 1Completed
- Sponsor
- DICE Therapeutics
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of simepdekinra in plaque psoriasis (3 cohorts), sponsored by DICE Therapeutics. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Infinity at Day 9, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 9 and 1 more. Started Jul 2024; status: completed.
02
Drugs
simepdekinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06503679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503679.